Search

Your search keyword '"Marques-Piubelli, Mario L."' showing total 277 results
Start Over Author "Marques-Piubelli, Mario L."
277 results on '"Marques-Piubelli, Mario L."'

1. Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents

Author

Marques-Piubelli, Mario L., Kumar, Bijender, Basar, Rafet, Panowski, Siler, Srinivasan, Surabhi, Norwood, Kevin, Prashad, Sacha, Szenes, Victoria, Balakumaran, Arun, Arandhya, Akanksha, Lu, Wei, Khan, Khaja, Duenas, Daniela, McAllen, Salome, Gomez, Javier A, Burks, Jared K., Acharyal, Sunil, Borthakur, Gautam, Wang, Wei-Lien, Wang, Wei, Wang, Sa, Solis, Luisa M., Marin, David, Rezvani, Katayoun, Daher, May, and Vega, Francisco

Published
2024
Full Text
View/download PDF

3. The Spectrum of Non-neoplastic Changes Associated With Breast Implants: Histopathology, Imaging, and Clinical Significance

Author

Marques-Piubelli, Mario L., Lyapichev, Kirill A., FNU, Aakash, Adrada, Beatriz, Stewart, John, Hunt, Kelly K., Clemens, Mark W., Iyer, Swaminathan, Wu, Yun, El Hussein, Siba, Xu, Jie, Ok, Chi Young, Li, Shaoying, Pierson, Diane M., Ferrufino-Schmidt, Maria C., Nahmod, Karen A., Yoga, Arthy, Hunsicker, Lisa, Evans, Mark G., Resetkova, Erika, Qiu, Lianqun, Khanlari, Mahsa, Garces, Sofia A., Bueso-Ramos, Carlos E., Medeiros, L. Jeffrey, and Miranda, Roberto N.

Published
2024
Full Text
View/download PDF

9. Supplementary Table 6 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

10. Supplementary Figure 6 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

11. Supplementary Figure 8 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

12. Supplementary Table 3 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

13. Supplementary Figure 1 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

14. Supplementary Table 1 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

15. Supplementary Figure 7 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

16. Data from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

17. Supplementary Figure 2 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

18. Supplementary Table 7 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

19. Supplementary Table 4 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

20. Supplementary Figure 5 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

21. Supplementary Table 2 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

22. Supplementary Figure 3 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

23. Supplementary Figure 4 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

24. Supplementary Table 5 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, primary, Duose, Dzifa Yawa, primary, Gonzalez-Kozlova, Edgar, primary, Redman, Mary W., primary, Chen, Hong, primary, Manyam, Ganiraju C., primary, Kumar, Gayatri, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Lazcano, Rossana, primary, Marques-Piubelli, Mario L., primary, Laberiano-Fernandez, Caddie, primary, Rojas, Frank, primary, Zhang, Baili, primary, Taing, Len, primary, Jhaveri, Aashna, primary, Geisberg, Jacob, primary, Altreuter, Jennifer, primary, Michor, Franziska, primary, Provencher, James, primary, Yu, Joyce, primary, Cerami, Ethan, primary, Moravec, Radim, primary, Kannan, Kasthuri, primary, Luthra, Rajyalakshmi, primary, Alatrash, Gheath, primary, Huang, Hsin-Hui, primary, Xie, Hui, primary, Patel, Manishkumar, primary, Nie, Kai, primary, Harris, Jocelyn, primary, Argueta, Kimberly, primary, Lindsay, James, primary, Biswas, Roshni, primary, Van Nostrand, Stephen, primary, Kim-Schulze, Seunghee, primary, Gray, Jhanelle E., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Gettinger, Scott, primary, Kelly, Karen, primary, Bazhenova, Lyudmila, primary, Gnjatic, Sacha, primary, Lee, J. Jack, primary, Zhang, Jianjun, primary, and Haymaker, Cara, primary

Published
2024
Full Text
View/download PDF

26. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Author

Marques-Piubelli, Mario L., Parra, Edwin R., Feng, Lei, Soto, Luisa Solis, Gallardo, Mariana, Gouni, Sushanth, Samaniego, Felipe, Noorani, Mansoor, Hagemeister, Fredrick B., Westin, Jason R., Lee, Hun Ju, Rodriguez, Maria A., Neelapu, Sattva S., Gunther, Jillian R., Fowler, Nathan H., Flowers, Christopher R., Wistuba, Ignacio I., Nastoupil, Loretta J., Vega, Francisco, and Strati, Paolo

Published
2022
Full Text
View/download PDF

28. Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease

Author

Evans, Mark G., Medeiros, L. Jeffrey, Marques-Piubelli, Mario L., Wang, Huan-You, Ortiz-Hidalgo, Carlos, Pina-Oviedo, Sergio, Morine, Angela, Clemens, Mark W., Hunt, Kelly K., Iyer, Swaminathan, Hu, Qinglong, Recavarren, Claudia, Demichelis, Roberta, Romero, Martha, Sohani, Aliyah R., Misialek, Michael, Amin, Mitual B., Bueso-Ramos, Carlos E., Carballo-Zarate, Adrian A., Lee, Hun J., Ok, Chi Young, Xu, Jie, and Miranda, Roberto N.

Published
2021
Full Text
View/download PDF

29. Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship

Author

Medeiros, L. Jeffrey, Marques-Piubelli, Mario L., Sangiorgio, Valentina F. I., Ruiz-Cordero, Roberto, Vega, Francisco, Feldman, Andrew L., Chapman, Jennifer R., Clemens, Mark W., Hunt, Kelly K., Evans, Mark G., Khoo, Christine, Lade, Stephen, Silberman, Mark, Morkowski, Jerzy, Pina, Edward M., Mills, Daniel C., Bates, Christopher M., Magno, Winston B., Sohani, Aliyah R., Sieling, Beth A., O’Donoghue, Joseph M., Bacon, Chris M., Patani, Neill, Televantou, Despina, Turner, Suzanne D., Johnson, Laura, MacNeill, Fiona, Wotherspoon, Andrew C., Iyer, Swaminathan P., Malpica, Luis E., Patel, Keyur P., Xu, Jie, and Miranda, Roberto N.

Published
2021
Full Text
View/download PDF

30. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Author

Parra, Edwin Roger, primary, Zhang, Jiexin, additional, Duose, Dzifa Yawa, additional, Gonzalez-Kozlova, Edgar, additional, Redman, Mary W., additional, Chen, Hong, additional, Manyam, Ganiraju C., additional, Kumar, Gayatri, additional, Zhang, Jianhua, additional, Song, Xingzhi, additional, Lazcano, Rossana, additional, Marques-Piubelli, Mario L., additional, Laberiano-Fernandez, Caddie, additional, Rojas, Frank, additional, Zhang, Baili, additional, Taing, Len, additional, Jhaveri, Aashna, additional, Geisberg, Jacob, additional, Altreuter, Jennifer, additional, Michor, Franziska, additional, Provencher, James, additional, Yu, Joyce, additional, Cerami, Ethan, additional, Moravec, Radim, additional, Kannan, Kasthuri, additional, Luthra, Rajyalakshmi, additional, Alatrash, Gheath, additional, Huang, Hsin-Hui, additional, Xie, Hui, additional, Patel, Manishkumar, additional, Nie, Kai, additional, Harris, Jocelyn, additional, Argueta, Kimberly, additional, Lindsay, James, additional, Biswas, Roshni, additional, Van Nostrand, Stephen, additional, Kim-Schulze, Seunghee, additional, Gray, Jhanelle E., additional, Herbst, Roy S., additional, Wistuba, Ignacio I., additional, Gettinger, Scott, additional, Kelly, Karen, additional, Bazhenova, Lyudmila, additional, Gnjatic, Sacha, additional, Lee, J. Jack, additional, Zhang, Jianjun, additional, and Haymaker, Cara, additional

Published
2024
Full Text
View/download PDF

31. Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides

Author

Marques-Piubelli, Mario L., primary, Navarrete, Jesus, additional, Ledesma, Debora A., additional, Hudgens, Courtney W., additional, Lazcano, Rossana N., additional, Alani, Ali, additional, Huen, Auris, additional, Duvic, Madeleine, additional, Nagarajan, Priyadharsini, additional, Aung, Phyu P., additional, Wistuba, Ignacio I., additional, Curry, Jonathan L., additional, Miranda, Roberto N., additional, and Torres-Cabala, Carlos A., additional

Published
2024
Full Text
View/download PDF

34. Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin.

Author

Cho, Woo Cheal, Saade, Rayan, Nagarajan, Priyadharsini, Aung, Phyu P., Milton, Denái R., Marques‐Piubelli, Mario L., Hudgens, Courtney, Ledesma, Debora, Nelson, Kelly, Ivan, Doina, Zhang, Miao, Torres‐Cabala, Carlos A., Campbell, Matthew, Alhalabi, Omar, Prieto, Victor G., Wistuba, Ignacio I., Esmaeli, Bita, and Curry, Jonathan L.

Subjects
CARCINOMA, BENIGN tumors, SEBACEOUS gland diseases, TRANSITIONAL cell carcinoma, DUCTAL carcinoma, BREAST
Abstract

Background: Enfortumab vedotin (EV) is an antibody‐drug conjugate directed against Nectin‐4 that is used to treat urothelial carcinoma. Nectin‐4 is inherently expressed in the skin and adnexal structures. Since therapeutic options for cutaneous adnexal carcinomas are limited, we sought to evaluate Nectin‐4 expression in adnexal carcinomas and benign adnexal neoplasms to identify tumors that are potentially targetable with EV. Methods: Eight sebaceous carcinomas (seven periocular and one lymph node metastasis), eight digital papillary adenocarcinomas, seven squamoid eccrine ductal carcinomas, eight poromas, eight trichilemmomas, and seven sebaceous adenomas were subjected to immunohistochemical staining for anti‐Nectin‐4 antibody. H‐scores for Nectin‐4 expression were calculated. Results: Benign adnexal neoplasms had a significantly lower mean (±SD) Nectin‐4 H‐score (142.6 ± 39.1) than did the adnexal carcinomas (198 ± 90.8; p = 0.006). Nectin‐4 was expressed in 91% (21/23) of adnexal carcinomas. Sebaceous carcinomas frequently exhibited high expression of Nectin‐4 (88% [7/8]), with a mean (±SD) H‐score (258.1 ± 58.4) significantly higher than those for digital papillary adenocarcinomas (197.5 ± 52.5; p = 0.035) and squamoid eccrine ductal carcinomas (131.4 ± 114.1; p = 0.031). Sebaceous carcinomas also had significantly higher H‐scores than did sebaceous adenomas (186.4 ± 25.0; p = 0.013). Conclusions: Increased Nectin‐4 expression in a subset of cutaneous adnexal carcinomas, particularly sebaceous carcinomas, reveals that EV is a potential therapeutic option for these tumors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Corrigendum to “Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship.” [Modern Pathology 34 (2021) 2154–2167]

Author

Medeiros, L. Jeffrey, primary, Marques-Piubelli, Mario L., additional, Sangiorgio, Valentina F.I., additional, Ruiz-Cordero, Roberto, additional, Vega, Francisco, additional, Feldman, Andrew L., additional, Chapman, Jennifer R., additional, Clemens, Mark W., additional, Hunt, Kelly K., additional, Evans, Mark G., additional, Khoo, Christine, additional, Lade, Stephen, additional, Silberman, Mark, additional, Morkowski, Jerzy, additional, Pina, Edward M., additional, Mills, Daniel C., additional, Bates, Christopher M., additional, Magno, Winston B., additional, Sohani, Aliyah R., additional, Sieling, Beth A., additional, O’Donoghue, Joseph M., additional, Bacon, Chris M., additional, Patani, Neill, additional, Televantou, Despina, additional, Turner, Suzanne D., additional, Johnson, Laura, additional, MacNeill, Fiona, additional, Wotherspoon, Andrew C., additional, Iyer, Swaminathan P., additional, Malpica, Luis E., additional, Patel, Keyur P., additional, Xu, Jie, additional, and Miranda, Roberto N., additional

Published
2023
Full Text
View/download PDF

38. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

Author

Gordon, Max J., primary, Feng, Lei, additional, Strati, Paolo, additional, Lee, Hun Ju, additional, Hagemeister, Fredrick B., additional, Westin, Jason R., additional, Samaniego, Felipe, additional, Marques‐Piubelli, Mario L., additional, Vega Vazquez, Francisco, additional, Parra Cuentas, Edwin R., additional, Solis‐Soto, Luisa M., additional, Ma, Wencai, additional, Wang, Jing, additional, Claret, Linda, additional, Averill, Barbara, additional, Ibanez, Karina, additional, Fayad, Luis E., additional, Flowers, Christopher R., additional, Green, Michael R., additional, Davis, R. Eric, additional, Neelapu, Sattva S., additional, Fowler, Nathan H., additional, and Nastoupil, Loretta J., additional

Published
2023
Full Text
View/download PDF

39. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

Author

Abbas, Hussein A., Hao, Dapeng, Tomczak, Katarzyna, Barrodia, Praveen, Im, Jin Seon, Reville, Patrick K., Alaniz, Zoe, Wang, Wei, Wang, Ruiping, Wang, Feng, Al-Atrash, Gheath, Takahashi, Koichi, Ning, Jing, Ding, Maomao, Beird, Hannah C., Mathews, Jairo T., Little, Latasha, Zhang, Jianhua, Basu, Sreyashi, Konopleva, Marina, Marques-Piubelli, Mario L., Solis, Luisa M., Parra, Edwin Roger, Lu, Wei, Tamegnon, Auriole, Garcia-Manero, Guillermo, Green, Michael R., Sharma, Padmanee, Allison, James P., Kornblau, Steven M., Rai, Kunal, Wang, Linghua, Daver, Naval, and Futreal, Andrew

Published
2021
Full Text
View/download PDF

40. Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses

Author

Romain, Gabrielle, Strati, Paolo, Rezvan, Ali, Fathi, Mohsen, Bandey, Irfan N., Adolacion, Jay R.T., Heeke, Darren, Liadi, Ivan, Marques-Piubelli, Mario L., Solis, Luisa M., Mahendra, Ankit, Vega, Francisco, Cooper, Laurence J.N., Singh, Harjeet, Mattie, Mike, Bot, Adrian, Neelapu, Sattva S., and Varadarajan, Navin

Subjects
T cells -- Physiological aspects -- Health aspects, Immune response -- Health aspects, Lymphomas -- Drug therapy -- Development and progression, Cancer -- Care and treatment, Cell adhesion molecules -- Physiological aspects -- Health aspects, Health care industry
Abstract

The in vivo persistence of adoptively transferred T cells is predictive of antitumor response. Identifying functional properties of infused T cells that lead to in vivo persistence and tumor eradication has remained elusive. We profiled CD19-specific chimeric antigen receptor (CAR) T cells as the infusion products used to treat large B cell lymphomas using high-throughput single-cell technologies based on time-lapse imaging microscopy in nanowell grids (TIMING), which integrates killing, cytokine secretion, and transcriptional profiling. Our results show that the directional migration of CD19-specific CAR T cells is correlated with multifunctionality. We showed that CD2 on T cells is associated with directional migration and that the interaction between CD2 on T cells and CD58 on lymphoma cells accelerates killing and serial killing. Consistent with this, we observed that elevated CD58 expression on pretreatment tumor samples in patients with relapsed or refractory large B cell lymphomas treated with CD19-specific CAR T cell therapy was associated with complete clinical response and survival. These results highlight the importance of studying dynamic T cell-tumor cell interactions in identifying optimal antitumor responses., Introduction T cells stably endowed with a genetically encoded chimeric antigen receptor (CAR) targeting CD19 have shown clinical responses in refractory B-lineage leukemias and lymphomas. The potential for durable remissions [...]

Published
2022
Full Text
View/download PDF

43. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

Author

Gordon, Max J., Feng, Lei, Strati, Paolo, Lee, Hun Ju, Hagemeister, Fredrick B., Westin, Jason R., Samaniego, Felipe, Marques‐Piubelli, Mario L., Vega Vazquez, Francisco, Parra Cuentas, Edwin R., Solis‐Soto, Luisa M., Ma, Wencai, Wang, Jing, Claret, Linda, Averill, Barbara, Ibanez, Karina, Fayad, Luis E., Flowers, Christopher R., Green, Michael R., and Davis, R. Eric

Subjects
MUCOSA-associated lymphoid tissue lymphoma, LENALIDOMIDE, BRUTON tyrosine kinase, RITUXIMAB, FOLLICULAR lymphoma
Abstract

Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non‐Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because standard treatments are not curative, patients often receive multiple lines of therapy with associated toxicity—rationally designed, combination therapies with curative potential are needed. The immunomodulatory drug lenalidomide was evaluated in combination with rituximab for the frontline treatment of FL in the phase 3 RELEVANCE study. Ibrutinib, an oral Bruton tyrosine kinase inhibitor, is active in NHL and was evaluated in combination with lenalidomide, rituximab, and ibrutinib (IRR) in a phase 1 study. Methods: The authors conducted an open‐label, phase 2 clinical trial of IRR for previously untreated FL and MZL. The primary end point was progression‐free survival (PFS) at 24 months. Results: This study included 48 participants with previously untreated FL grade 1–3a (N = 38), or MZL (N = 10). Participants received 12, 28‐day cycles of lenalidomide (15 mg, days 1–21 cycle 1; 20 mg, cycles 2–12), rituximab (375 mg/m2 weekly in cycle 1; day 1 cycles 2‐12), and ibrutinib 560 mg daily. With a median follow‐up of 65.3 months, the estimated PFS at 24 months was 78.8% (95% confidence interval [CI], 68.0%–91.4%) and 60‐month PFS was 59.7% (95% CI, 46.6%–76.4%). One death occurred unrelated to disease progression. Grade 3–4 adverse events were observed in 64.6%, including 50% with grade 3–4 rash. Conclusions: IRR is highly active as frontline therapy for FL and MZL. Compared to historical results with lenalidomide and rituximab, PFS is similar with higher grade 3–4 toxicity, particularly rash. The study was registered with ClinicalTrials.gov (NCT02532257). After 5 years of follow‐up from a phase 2 clinical trial of ibrutinib, lenalidomide, and rituximab in previously untreated patients with follicular and marginal zone lymphoma, the 5‐year progression‐free survival rate was 59.7% and the overall survival rate was 97.9%. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Data from Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors

Author

Sousa, Luana Guimaraes, primary, McGrail, Daniel J., primary, Lazar Neto, Felippe, primary, Li, Kaiyi, primary, Marques-Piubelli, Mario L., primary, Ferri-Borgogno, Sammy, primary, Dai, Hui, primary, Mitani, Yoshitsugu, primary, Spardy Burr, Nicole, primary, Cooper, Zachary A., primary, Kinneer, Krista, primary, Cortez, Maria Angelica, primary, Lin, Shiaw-Yih, primary, Bell, Diana, primary, El Naggar, Adel, primary, Burks, Jared, primary, and Ferrarotto, Renata, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figures 1 from Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors

Author

Sousa, Luana Guimaraes, primary, McGrail, Daniel J., primary, Lazar Neto, Felippe, primary, Li, Kaiyi, primary, Marques-Piubelli, Mario L., primary, Ferri-Borgogno, Sammy, primary, Dai, Hui, primary, Mitani, Yoshitsugu, primary, Spardy Burr, Nicole, primary, Cooper, Zachary A., primary, Kinneer, Krista, primary, Cortez, Maria Angelica, primary, Lin, Shiaw-Yih, primary, Bell, Diana, primary, El Naggar, Adel, primary, Burks, Jared, primary, and Ferrarotto, Renata, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Data 1 from Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors

Author

Sousa, Luana Guimaraes, primary, McGrail, Daniel J., primary, Lazar Neto, Felippe, primary, Li, Kaiyi, primary, Marques-Piubelli, Mario L., primary, Ferri-Borgogno, Sammy, primary, Dai, Hui, primary, Mitani, Yoshitsugu, primary, Spardy Burr, Nicole, primary, Cooper, Zachary A., primary, Kinneer, Krista, primary, Cortez, Maria Angelica, primary, Lin, Shiaw-Yih, primary, Bell, Diana, primary, El Naggar, Adel, primary, Burks, Jared, primary, and Ferrarotto, Renata, primary

Published
2023
Full Text
View/download PDF

47. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells

Author

Strati, Paolo, primary, Li, Xubin, additional, Deng, Qing, additional, Marques-Piubelli, Mario L., additional, Henderson, Jared, additional, Watson, Grace, additional, Deaton, Laurel, additional, Cain, Taylor, additional, Yang, Haopeng, additional, Ravanmehr, Vida, additional, Fayad, Luis E., additional, Iyer, Swaminathan P., additional, Nastoupil, Loretta J., additional, Hagemeister, Frederick B., additional, Parra, Edwin R., additional, Saini, Neeraj, additional, Takahashi, Koichi, additional, Fowler, Nathan H., additional, Westin, Jason R., additional, Steiner, Raphael E., additional, Nair, Ranjit, additional, Flowers, Christopher R., additional, Wang, Linghua, additional, Ahmed, Sairah, additional, Al-Atrash, Gheath, additional, Vega, Francisco, additional, Neelapu, Sattva S., additional, and Green, Michael R., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results